Immvira Bioscience is an anti-tumor drug carrier developer in Cayman. It is mainly engaged in the clinical research and development of carrier technology as a potential cancer therapy. It is committed to developing original anti-tumor drug carriers through the drug’s own anti-tumor mechanism and tumor microenvironment improvement, including replication and non-replicating herpesvirus vectors, exosome delivery vectors, and antitumor vaccines. Recently, Immvira Bioscience received US$8 million in strategic investment from China Merchants China Fund.
This article is reproduced from: https://www.itjuzi.com/investevent/13583415
This site is for inclusion only, and the copyright belongs to the original author.